AEON Biopharma, Inc. Announces Reverse Stock Split
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company, has announced a 1-for-72 reverse stock split of its common stock, effective February 26, 2025. The decision was approved by the company's Board of Directors following stockholder authorization at a Special Meeting on February 24, 2025, where shareholders approved a split ratio range of 1-for-5 to 1-for-150.
The reverse split aims to increase the selling price of AEON's common stock to maintain compliance with NYSE American requirements. Trading will continue under the symbol 'AEON' but with a new CUSIP number [00791X 209]. Stockholders' ownership percentages will remain unchanged, except for fractional shares, which will be rounded up to the nearest whole share.
AEON Biopharma (NYSE: AEON), una compagnia biofarmaceutica in fase clinica, ha annunciato uno scorporo azionario inverso 1-per-72 delle sue azioni ordinarie, che entrerà in vigore il 26 febbraio 2025. La decisione è stata approvata dal Consiglio di Amministrazione dell'azienda dopo l'autorizzazione degli azionisti in un'Assemblea Straordinaria il 24 febbraio 2025, dove gli azionisti hanno approvato un intervallo di rapporto di scorporo da 1-per-5 a 1-per-150.
Lo scorporo inverso ha lo scopo di aumentare il prezzo di vendita delle azioni ordinarie di AEON per mantenere la conformità con i requisiti della NYSE American. Le negoziazioni continueranno sotto il simbolo 'AEON', ma con un nuovo numero CUSIP [00791X 209]. Le percentuali di proprietà degli azionisti rimarranno invariate, ad eccezione delle azioni frazionarie, che saranno arrotondate al numero intero più vicino.
AEON Biopharma (NYSE: AEON), una compañía biofarmacéutica en etapa clínica, ha anunciado un dividendo inverso de acciones 1-por-72 de sus acciones ordinarias, que entrará en vigor el 26 de febrero de 2025. La decisión fue aprobada por la Junta Directiva de la compañía tras la autorización de los accionistas en una Reunión Especial el 24 de febrero de 2025, donde los accionistas aprobaron un rango de relación de división de 1-por-5 a 1-por-150.
El dividendo inverso tiene como objetivo aumentar el precio de venta de las acciones ordinarias de AEON para mantener el cumplimiento de los requisitos de NYSE American. Las operaciones continuarán bajo el símbolo 'AEON', pero con un nuevo número CUSIP [00791X 209]. Los porcentajes de propiedad de los accionistas permanecerán sin cambios, excepto por las acciones fraccionarias, que se redondearán al número entero más cercano.
AEON Biopharma (NYSE: AEON), 임상 단계의 생명공학 회사가 1대 72 역주식 분할을 발표했으며, 이는 2025년 2월 26일부터 시행됩니다. 이 결정은 2025년 2월 24일의 특별 회의에서 주주 승인을 받은 후 회사 이사회의 승인을 받았습니다. 주주들은 1대 5에서 1대 150까지의 분할 비율 범위를 승인했습니다.
역주식 분할은 AEON의 보통주 판매 가격을 높여 NYSE American의 요구 사항을 준수하기 위한 것입니다. 거래는 'AEON' 기호 아래 계속되지만 새로운 CUSIP 번호 [00791X 209]가 부여됩니다. 주주들의 소유 비율은 변경되지 않지만, 분할 주식은 가장 가까운 정수로 반올림됩니다.
AEON Biopharma (NYSE: AEON), une entreprise biopharmaceutique en phase clinique, a annoncé un scission d'actions inversée de 1 pour 72 de ses actions ordinaires, qui prendra effet le 26 février 2025. La décision a été approuvée par le conseil d'administration de l'entreprise après l'autorisation des actionnaires lors d'une réunion spéciale le 24 février 2025, où les actionnaires ont approuvé un rapport de scission allant de 1 pour 5 à 1 pour 150.
La scission inversée vise à augmenter le prix de vente des actions ordinaires d'AEON afin de maintenir la conformité avec les exigences de la NYSE American. Les transactions continueront sous le symbole 'AEON', mais avec un nouveau numéro CUSIP [00791X 209]. Les pourcentages de propriété des actionnaires resteront inchangés, sauf pour les actions fractionnaires, qui seront arrondies à l'action entière la plus proche.
AEON Biopharma (NYSE: AEON), ein biopharmazeutisches Unternehmen in klinischer Phase, hat einen 1-zu-72 Rücksplitter seiner Stammaktien angekündigt, der am 26. Februar 2025 wirksam wird. Die Entscheidung wurde vom Vorstand des Unternehmens nach der Genehmigung durch die Aktionäre in einer außerordentlichen Hauptversammlung am 24. Februar 2025 getroffen, bei der die Aktionäre ein Splitverhältnis von 1-zu-5 bis 1-zu-150 genehmigten.
Der Rücksplitter zielt darauf ab, den Verkaufspreis der Stammaktien von AEON zu erhöhen, um die Anforderungen der NYSE American einzuhalten. Der Handel wird weiterhin unter dem Symbol 'AEON' stattfinden, jedoch mit einer neuen CUSIP-Nummer [00791X 209]. Die Eigentumsanteile der Aktionäre bleiben unverändert, mit Ausnahme von Bruchstücken, die auf die nächste ganze Aktie aufgerundet werden.
- Maintains NYSE American listing compliance through stock price adjustment
- No change in shareholders' ownership percentage post-split
- Indicates potential stock price weakness necessitating reverse split
- Risk of reduced stock liquidity post-split
Insights
The announced 1-for-72 reverse stock split signals significant challenges for AEON Biopharma. The chosen ratio is particularly aggressive, falling in the upper range of the approved 1:5 to 1:150 spectrum, which typically indicates substantial pressure to meet exchange listing requirements. While this action will mechanically boost the share price by reducing the number of outstanding shares, historical data suggests that reverse splits often precede continued underperformance.
The timing and execution of this corporate action carry several critical implications:
- The NYSE American typically requires stocks to maintain a minimum bid price of
$1.00 . This reverse split appears to be a defensive move to ensure continued listing compliance rather than a proactive strategic decision. - The substantial 1:72 ratio could significantly impact trading dynamics. Reduced float often leads to increased volatility and wider bid-ask spreads, potentially affecting liquidity for retail investors.
- Institutional investors typically view reverse splits skeptically, as they're often associated with distressed companies. This could impact institutional ownership levels and future capital raising capabilities.
While the mathematical impact on market capitalization is neutral, reverse splits historically correlate with negative market perception and increased short-term volatility. For biotechnology companies like AEON, maintaining exchange listing is important for access to capital markets, especially given their development-stage status and need for ongoing funding.
The decision to round up fractional shares to the nearest whole share, while seemingly minor, could create a small but notable dilutive effect, particularly given the high split ratio. This detail warrants attention from current shareholders calculating their post-split positions.
IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that the Company’s Board of Directors approved a 1-for-72 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value
The Reverse Stock Split will take legal effect at 12:01 A.M. Eastern Time on February 26, 2025, and the Company's Common Stock will open for trading on the NYSE American on February 26, 2025, on a post-split basis, under the existing ticker symbol "AEON" but with a new CUSIP number [00791X 209].
At the Company’s Special Meeting of Stockholders (the “Special Meeting”) held on February 24, 2025, the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to effect a reverse stock split of its Common Stock at a ratio of between 1-for-5 to 1-for-150, with the ratio within such range to be determined at the discretion of the Company’s Board. Following the Special Meeting, the Board approved a final split ratio of 1-for-72. Following the Reverse Stock Split, the ownership percentage of each stockholder will remain unchanged, other than with respect to fractional shares. No fractional shares will be issued in connection with the Reverse Stock Split, with any fractional shares instead being rounded up to the nearest whole share.
Additional details regarding the Company’s Reverse Stock Split can be found in the Current Report on Form 8-K filed on February 24, 2025 with the Securities and Exchange Commission (the “SEC”).
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON’s future capital requirements; (iii) AEON’s ability to raise financing in the future; (iv) AEON’s ability to continue to meet continued stock exchange listing standards; (v) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vi) the Company’s ability to present a Plan that will be accepted by NYSE Regulation; and (vii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at www.sec.gov.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
FAQ
What is the ratio of AEON Biopharma's reverse stock split announced in February 2025?
When will AEON's reverse stock split take effect?
Why did AEON Biopharma implement a reverse stock split?
How will AEON's reverse stock split affect existing shareholders?
Will AEON's stock symbol change after the reverse split?
